A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease
- Publisher's listprice EUR 35.95
-
14 910 Ft (14 200 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 1 491 Ft off)
- Discounted price 13 419 Ft (12 780 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
14 910 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Elsevier Science
- Date of Publication 27 April 2017
- ISBN 9780128127964
- Binding Paperback
- No. of pages160 pages
- Size 228x152 mm
- Weight 250 g
- Language English 0
Categories
Long description:
"
Cancer, dementia, and cardiovascular disease are responsible for almost two million deaths each year in the United States alone and represent the largest immediate threat to humanity. Over the last century, we have made spectacular advances that have transformed our society - splitting the atom, space travel, telecommunications, and the Internet - but with medical research focused mostly on science for the sake of science, it has yielded precious few cures.
A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease represents a ""first of its kind"" effort to address both the reasons for this and to posit solutions to fix our broken system, in an effort to finally end this cure crisis. Dr. Marangos draws on 45 years of experience in every aspect of the biomedical R&D field, from basic drug discovery research at the NIH to the co-founding of five drug companies. He has published 252 research papers and edited four books on drug discovery, is co-inventor on 14 patents, and founded ""The Journal of Molecular Neuroscience"". He argues that from a development perspective, the regulatory, patent, and legal hurdles that force industry to pursue so-called ""me-too"" drugs rather than cures for terminal diseases must be re-thought. Leadership accountability, strategy, focus, and urgency need to be re-evaluated, and major reforms to the NIH, FDA, and patent codes are proposed.to remedy these impediments to cures. Written for anyone frustrated with the seemingly endless threat of terminal disease, this book seeks to inform, energize, and provide the rationale for the public and industry stakeholders, as well as clinicians and researchers, to resurrect the physician-patient relationship and demand that we get serious about ridding society of this scourge on humanity.
This work contains the views and opinions of the author and are in no way intended to harm the reputation of any person, agency, organization, or commercial entity discussed herein.
www.cureterminaldisease.com
" MoreTable of Contents:
Part A. The Reasons for Failure1. The Medical R&D Fiasco2. Academia Is Marching to the Wrong Drummer3. Mavericks Versus the Establishment4. The Strangled Unincentivized Drug Industry5. The FDA Roadblock to Cures6. The Liability Barrier
Part B. Towards Solutions7. Cleaning Up the Academic Research Quagmire8. Reforming the FDA9. Enabling the Drug Industry10. Patent and Liability Reform11. The Public Will Make It Happen
More
